Canaccord Genuity Reiterates Buy on Bicycle Therapeutics, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Bill Maughan reiterated a Buy rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a $60 price target.
February 21, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating and a $60 price target on Bicycle Therapeutics.
The reiteration of a Buy rating and maintenance of a $60 price target by a reputable analyst firm like Canaccord Genuity is likely to instill confidence in investors about Bicycle Therapeutics' potential, positively impacting its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100